| Maggie A Shatilla, MD | |
|
509 North St, Bamberg, SC 29003-1330 | |
| (803) 245-6706 | |
| (803) 245-6731 |
| Full Name | Maggie A Shatilla |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Location | 509 North St, Bamberg, South Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891839775 | NPI | - | NPPES |
| 194783 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 19478 (South Carolina) | Primary |
| Entity Name | Orthopedic Associates Of The Lowcountry Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528292638 PECOS PAC ID: 4183779556 Enrollment ID: O20090909000030 |
News Archive
Researchers at Mayo Clinic have identified a genetic promoter of cancer that drives a major form of lung cancer.
Cancer Research UK scientists have tamed a virus so that it attacks and destroys cancer cells but does not harm healthy cells, according to a paper published in PLoS Pathogens, today.
Our fat cells, technically referred to as adipocytes, play an essential role in regulating energy balance in our body.
Sarah Cannon Research Institute (SCRI) investigators will present the findings of several important blood cancer trials during the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego December 10-13.
RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.
› Verified 5 days ago
| Entity Name | South Carolina Group Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609212232 PECOS PAC ID: 1759525777 Enrollment ID: O20130912000800 |
News Archive
Researchers at Mayo Clinic have identified a genetic promoter of cancer that drives a major form of lung cancer.
Cancer Research UK scientists have tamed a virus so that it attacks and destroys cancer cells but does not harm healthy cells, according to a paper published in PLoS Pathogens, today.
Our fat cells, technically referred to as adipocytes, play an essential role in regulating energy balance in our body.
Sarah Cannon Research Institute (SCRI) investigators will present the findings of several important blood cancer trials during the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego December 10-13.
RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maggie A Shatilla, MD 509 North St, Bamberg, SC 29003-1330 Ph: (803) 245-6706 | Maggie A Shatilla, MD 509 North St, Bamberg, SC 29003-1330 Ph: (803) 245-6706 |
News Archive
Researchers at Mayo Clinic have identified a genetic promoter of cancer that drives a major form of lung cancer.
Cancer Research UK scientists have tamed a virus so that it attacks and destroys cancer cells but does not harm healthy cells, according to a paper published in PLoS Pathogens, today.
Our fat cells, technically referred to as adipocytes, play an essential role in regulating energy balance in our body.
Sarah Cannon Research Institute (SCRI) investigators will present the findings of several important blood cancer trials during the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego December 10-13.
RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.
› Verified 5 days ago
Dr. Vishal Abiraj, MBBS Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 185 Mcgee St, Bamberg, SC 29003 Phone: 803-956-6100 Fax: 803-632-1209 |